首页> 外文期刊>Biomacromolecules >Multimeric Disintegrin Protein Polymer Fusions That Target Tumor Vasculature
【24h】

Multimeric Disintegrin Protein Polymer Fusions That Target Tumor Vasculature

机译:靶向肿瘤脉管系统的多聚体解毒蛋白聚合物融合

获取原文
获取原文并翻译 | 示例
           

摘要

Recombinant protein therapeutics have increased in number and frequency since the introduction of human insulin, 25 years ago. Presently, proteins and peptides are commonly used in the clinic. However, the incorporation of peptides into clinically approved nanomedicines has been limited. Reasons for this include the challenges of decorating pharmaceutical-grade nanoparticles with proteins by a process that is robust, scalable, and cost-effective. As an alternative to covalent bioconjugation between a protein and nanoparticle, we report that biologically active proteins may themselves mediate the formation of small multimers through steric stabilization by large protein polymers. Unlike multistep purification and bioconjugation, this approach is completed during biosynthesis. As proof-of-principle, the disintegrin protein called vicrostatin (VCN) was fused to an elastin-Iike polypeptide (A192). A significant fraction of fusion proteins self-assembled into multimers with a hydrodynamic radius of 15.9 nm, The A192-VCN fusion proteins compete specifically for cell-surface integrins on human umbilical vein endothelial cells (HUVECs) and two breast cancer cell lines, MDA-MB-231 and *MDA-MB-435. Confocal microscopy revealed that, unlike linear RGD-containing protein polymers, the disintegrin fusion protein undergoes rapid cellular internalization. To explore their potential clinical applications, fusion proteins were characterized using small animal positron emission tomography (microPET). Passive tumor accumulation was observed for control protein polymers; however, the tumor accumulation of A192-VCN was saturable, which is consistent with integrin-mediated binding. The fusion of a protein polymer and disintegrin results in a higher intratumoral contrast compared to free VCN or A192 alone. Given the diversity of disintegrin proteins with specificity for various cell-surface integrins, disintegrin fusions are a new source of biomaterials with potential diagnostic and therapeutic applications.
机译:自25年前的人胰岛素引入以来,重组蛋白质治疗剂的数量和频率增加。目前,蛋白质和肽通常用于诊所。然而,肽将肽掺入临床批准的纳米海内西有限。其中的原因包括通过稳健,可扩展性和成本效益的过程用蛋白质装饰药物级纳米颗粒的挑战。作为蛋白质和纳米颗粒之间的共价生物缀合的替代方案,我们认为生物活性蛋白质本身可以通过大蛋白质聚合物通过空间稳定来介导小型多聚体的形成。与多步净化和生物谐波不同,这种方法在生物合成期间完成。作为原则上,称为viCrostatin(VCN)的解胶蛋白融合给弹性蛋白 - Iike多肽(A192)。一部分融合蛋白自组装成具有15.9nm的流体动力半径的多聚体,A192-VCN融合蛋白特别用于人脐静脉内皮细胞(HUVECS)和两种乳腺癌细胞系上的细胞表面整年蛋白,MDA- MB-231和* MDA-MB-435。共聚焦显微镜显示,与含线性RGD的蛋白质聚合物不同,解胶蛋白融合蛋白经历快速的细胞内化。为了探讨其潜在的临床应用,使用小动物正电子发射断层扫描(MicroPet)以融合蛋白为特征。对照蛋白质聚合物观察被动肿瘤积累;然而,A192-VCN的肿瘤积累是可饱和的,这与整联蛋白介导的结合一致。与单独的游离VCN或A192相比,蛋白质聚合物和Disintegin的融合导致更高的肿瘤内对比度。鉴于各种细胞表面整年蛋白特异性的DisIntegin蛋白的多样性,Disintegrin融合是具有潜在诊断和治疗应用的生物材料的新来源。

著录项

  • 来源
    《Biomacromolecules》 |2014年第7期|共12页
  • 作者单位

    Department of Pharmacology and Pharmaceutical Sciences School of Pharmacy Malaysian Nuclear Agency Bangi 43000 Kajang Selangor Malaysia;

    Department of Pharmacology and Pharmaceutical Sciences School of Pharmacy Malaysian Nuclear Agency Bangi 43000 Kajang Selangor Malaysia;

    Department of Biochemistry and Molecular Biology Norris Comprehensive Cancer Center Keck School of Medicine Los Angeles California 90033 United States;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分子生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号